Triple
T2371048
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Rituxan |
E46089
|
entity |
| Predicate | hasBiosimilar |
P37220
|
FINISHED |
| Object |
Truxima
Truxima is a monoclonal antibody biosimilar to rituximab used to treat certain cancers and autoimmune diseases by targeting the CD20 protein on B cells.
|
E46089
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Truxima | Statement: [Rituxan, hasBiosimilar, Truxima]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Truxima Context triple: [Rituxan, hasBiosimilar, Truxima]
-
A.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
B.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
C.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
D.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
-
E.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Truxima Triple: [Rituxan, hasBiosimilar, Truxima]
Generated description
Truxima is a monoclonal antibody biosimilar to rituximab used to treat certain cancers and autoimmune diseases by targeting the CD20 protein on B cells.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Truxima Target entity description: Truxima is a monoclonal antibody biosimilar to rituximab used to treat certain cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
A.
Rituxan
chosen
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
B.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
C.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
D.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
-
E.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
- F. None of above.
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69a88a145268819083e2736cb835c696 |
completed | March 4, 2026, 7:37 p.m. |
| NER | Named-entity recognition | batch_69abc76f5aec8190867d621e6849258c |
completed | March 7, 2026, 6:36 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69aeb3c81430819081654a90df17c5c0 |
completed | March 9, 2026, 11:49 a.m. |
| NEDg | Description generation | batch_69aeb4a5011c8190bda6c487dab73131 |
completed | March 9, 2026, 11:53 a.m. |
| NED2 | Entity disambiguation (via description) | batch_69aeb59d0e5c819080bf5b34946b68ac |
completed | March 9, 2026, 11:57 a.m. |
Created at: March 4, 2026, 7:56 p.m.